Till sidinnehåll
Inloggad som:

CA0881007-Myelom

Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.

CA0881007-Myelom
A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of BMS-986393, a GPRC5Ddirected CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants with Relapsed or Refractory and Lenalidomiderefractory Multiple Myeloma
A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of BMS-986393, a GPRC5Ddirected CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants with Relapsed or Refractory and Lenalidomiderefractory Multiple Myeloma
PLACEHOLDER
Mer information om studien för vårdgivare
Behandling
Fas 3
Palliativ
Företag
Tillbaka till listan